Z

Zhejiang Xianju Pharmaceutical Co Ltd
SZSE:002332

Watchlist Manager
Zhejiang Xianju Pharmaceutical Co Ltd
SZSE:002332
Watchlist
Price: 10.07 CNY 1% Market Closed
Market Cap: 10B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Zhejiang Xianju Pharmaceutical Co Ltd stock under the Base Case scenario is 15.5 CNY. Compared to the current market price of 10.07 CNY, Zhejiang Xianju Pharmaceutical Co Ltd is Undervalued by 35%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
15.5 CNY
Undervaluation 35%
Relative Value
Price
Z
Worst Case
Base Case
Best Case

Valuation Multiples

2.4
P/S
P/S
Price to Sales
2.4
vs History
69
vs Industry
46
Median 3Y
2.6
Median 5Y
2.8
Industry
2.4
Forward
2.3
More Details
16
P/E
P/E
Price to Earnings
16
vs History
74
vs Industry
30
Median 3Y
17
Median 5Y
18.6
Industry
20.5
Forward
14.2
More Details
30.8
P/OCF
P/OCF
Price to OCF
30.8
vs History
9
vs Industry
14
Median 3Y
18.4
Median 5Y
18.3
Industry
15.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
11
Median 3Y
-34.8
Median 5Y
35
Industry
22.6
More Details
1.7
P/B
P/B
Price to Book Value
1.7
vs History
92
vs Industry
45
Median 3Y
2
Median 5Y
2.2
Industry
2
More Details
2.1
EV/S
EV/S
Enterprise Value to Sales
2.1
vs History
74
vs Industry
48
Median 3Y
2.2
Median 5Y
2.5
Industry
2.5
Forward
2
More Details
3.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.9
vs History
69
vs Industry
50
Median 3Y
3.9
Median 5Y
4.6
Industry
4.9
More Details
12.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
12.2
vs History
82
vs Industry
29
Median 3Y
13.7
Median 5Y
15.4
Industry
12.6
Forward
8.8
More Details
12.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
12.2
vs History
82
vs Industry
33
Median 3Y
13.7
Median 5Y
15.4
Industry
15.6
Forward
10.8
More Details
27
EV/OCF
EV/OCF
Enterprise Value to OCF
27
vs History
11
vs Industry
16
Median 3Y
16.2
Median 5Y
16.6
Industry
13.9
More Details
121.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
121.4
vs History
4
vs Industry
4
Median 3Y
30.1
Median 5Y
28.5
Industry
17.7
More Details
1.6
EV/IC
EV/IC
Enterprise Value to IC
1.6
vs History
85
vs Industry
41
Median 3Y
2
Median 5Y
2.1
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Zhejiang Xianju Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Zhejiang Xianju Pharmaceutical Co Ltd
SZSE:002332
10B CNY 2.4 16 12.2 12.2
US
Eli Lilly and Co
NYSE:LLY
807.6B USD 17.9 76.3 44.3 48.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
387.6B USD 4.4 27.6 12.9 16.9
DK
Novo Nordisk A/S
CSE:NOVO B
2.2T DKK 7.7 22.1 14.6 16.6
CH
Roche Holding AG
SIX:ROG
242B CHF 4.1 21 11.7 13.9
UK
AstraZeneca PLC
LSE:AZN
174.6B GBP 4.2 32.1 126.8 193.6
CH
Novartis AG
SIX:NOVN
196B CHF 4.3 18.6 11.2 14.4
US
Merck & Co Inc
NYSE:MRK
222.5B USD 3.5 13 8.8 10.4
IE
Endo International PLC
LSE:0Y5F
167.6B USD 72.3 -57.3 267.5 670.8
US
Pfizer Inc
NYSE:PFE
144.8B USD 2.3 18 8.6 12.3
P/E Multiple
Earnings Growth PEG
CN
Z
Zhejiang Xianju Pharmaceutical Co Ltd
SZSE:002332
Average P/E: 27.2
16
21%
0.8
US
Eli Lilly and Co
NYSE:LLY
76.3
48%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
27.6
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
22.1
19%
1.2
CH
Roche Holding AG
SIX:ROG
21
16%
1.3
UK
AstraZeneca PLC
LSE:AZN
32.1
36%
0.9
CH
Novartis AG
SIX:NOVN
18.6
16%
1.2
US
Merck & Co Inc
NYSE:MRK
13
17%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
18
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Z
Zhejiang Xianju Pharmaceutical Co Ltd
SZSE:002332
Average EV/EBITDA: 396.8
12.2
30%
0.4
US
Eli Lilly and Co
NYSE:LLY
44.3
30%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.9
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
15%
1
CH
Roche Holding AG
SIX:ROG
11.7
8%
1.5
UK
AstraZeneca PLC
LSE:AZN
126.8
9%
14.1
CH
Novartis AG
SIX:NOVN
11.2
5%
2.2
US
Merck & Co Inc
NYSE:MRK
8.8
9%
1
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.6
3%
2.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Z
Zhejiang Xianju Pharmaceutical Co Ltd
SZSE:002332
Average EV/EBIT: 1 701.1
12.2
21%
0.6
US
Eli Lilly and Co
NYSE:LLY
48.9
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.9
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
16.6
16%
1
CH
Roche Holding AG
SIX:ROG
13.9
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
193.6
21%
9.2
CH
Novartis AG
SIX:NOVN
14.4
8%
1.8
US
Merck & Co Inc
NYSE:MRK
10.4
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.3
10%
1.2

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 241,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.